147 related articles for article (PubMed ID: 33087490)
41. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
42. Development of thymic tumor in [LSL:Kras
Liot S; El Kholti N; Balas J; Genestier L; Verrier B; Valcourt U; Lambert E
Sci Rep; 2021 Jul; 11(1):15075. PubMed ID: 34302028
[TBL] [Abstract][Full Text] [Related]
43. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
[TBL] [Abstract][Full Text] [Related]
44. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma.
Kotopoulis S; Stigen E; Popa M; Safont MM; Healey A; Kvåle S; Sontum P; Gjertsen BT; Gilja OH; McCormack E
J Control Release; 2017 Jan; 245():70-80. PubMed ID: 27871988
[TBL] [Abstract][Full Text] [Related]
45. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
[TBL] [Abstract][Full Text] [Related]
46. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma.
Oshima Y; Sano M; Kajiwara I; Ichimaru Y; Itaya T; Kuramochi T; Hayashi E; Kim J; Kitajima O; Masugi Y; Masamune A; Ijichi H; Ishii Y; Suzuki T
Br J Anaesth; 2022 Apr; 128(4):679-690. PubMed ID: 35120712
[TBL] [Abstract][Full Text] [Related]
47. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
48. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
[TBL] [Abstract][Full Text] [Related]
49. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
[TBL] [Abstract][Full Text] [Related]
50. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
51. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice.
Hedegger K; Algül H; Lesina M; Blutke A; Schmid RM; Schneider MR; Dahlhoff M
Mol Oncol; 2020 Aug; 14(8):1653-1669. PubMed ID: 32335999
[TBL] [Abstract][Full Text] [Related]
52. Mitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer.
Wang Q; Li M; Gan Y; Jiang S; Qiao J; Zhang W; Fan Y; Shen Y; Song Y; Meng Z; Yao M; Gu J; Zhang Z; Tu H
Theranostics; 2020; 10(5):2141-2157. PubMed ID: 32089737
[No Abstract] [Full Text] [Related]
53. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
54. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
55. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE
Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980
[TBL] [Abstract][Full Text] [Related]
56. ANGPTL4 accelerates KRAS
Yan HH; Jung KH; Lee JE; Son MK; Fang Z; Park JH; Kim SJ; Kim JY; Lim JH; Hong SS
Cancer Lett; 2021 Oct; 519():185-198. PubMed ID: 34311032
[TBL] [Abstract][Full Text] [Related]
57. Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61.
Sano M; Driscoll DR; DeJesus-Monge WE; Quattrochi B; Appleman VA; Ou J; Zhu LJ; Yoshida N; Yamazaki S; Takayama T; Sugitani M; Nemoto N; Klimstra DS; Lewis BC
Neoplasia; 2016 Dec; 18(12):785-794. PubMed ID: 27889647
[TBL] [Abstract][Full Text] [Related]
58. Tumor-neuroglia interaction promotes pancreatic cancer metastasis.
Su D; Guo X; Huang L; Ye H; Li Z; Lin L; Chen R; Zhou Q
Theranostics; 2020; 10(11):5029-5047. PubMed ID: 32308766
[No Abstract] [Full Text] [Related]
59. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer.
Goetze RG; Buchholz SM; Ou N; Zhang Q; Patil S; Schirmer M; Singh SK; Ellenrieder V; Hessmann E; Lu QB; Neesse A
Cells; 2019 Jun; 8(6):. PubMed ID: 31181844
[No Abstract] [Full Text] [Related]
60. Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.
Mohammed A; Janakiram NB; Suen C; Stratton N; Lightfoot S; Singh A; Pathuri G; Ritchie R; Madka V; Rao CV
Mol Carcinog; 2019 Oct; 58(10):1908-1918. PubMed ID: 31313401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
